Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01397890 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

793

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: Budesonide/formoterol (Symbicort® Turbuhaler®)
DRUG: Tiotropium (SpirivaTM)

Sponsor

AstraZeneca